急性心肌梗死冠脉内与静脉溶栓疗效及安全性对比研究

Comparison of efficacy and safety of coro-nary thrombolytic and intravenous throm-bolytic therapy in treatment-of acute myocardial infarction

目的 评价尿激酶 (UK)冠脉内与静脉溶栓治疗急性心肌梗死 (AMI)的临床疗效及安全性。方法 58例AMI患者随机分为冠脉溶栓组 (A组 )及静脉溶栓组 (B组 )各 2 9例 ,分别给予UK治疗。结果 心肌梗死相关血管再通率A组 82 .8%与B组 62 .1 %比较 ,P <0 .0 5。但出血并发症B组 1 0 .3%与A组 3 .5%相比较 ,P <0 .0 5。结论 冠脉内溶栓治疗AMI安全有效的 ,可明显改善病人近期。

Objective To evaluate the clinical efficacy and safety of coronary artery and intravenous thrombolyt:therapy using urokinase (UK)in patients with acute myocardial infarction (AMI). Methods 58 cases were divided into coronary thrombolytic group A(29cases)and intravenous thrombolytic group B(29 cases),which were treated with UK,respetcively. Results The clinical reperfursion rates of infarct related arteries in group A and group B were 82.8% and 62.1% respectively (P<0.05),but bleeding rate in group A and groupB was 3.5% and 10.30%(P<0.05)。 Conclusion The results suggested that coronary artery thrombolytic therapy was effective and safe for AMI.The short term and one year outcome was promising.